

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) An isolated human antibody, comprising:
human immunoglobulin VH-chain CDR1, CDR2, and CDR3 of a polypeptide
consisting of amino-acid sequences represented by SEQ ID NOS: 4, 5, and 6,
respectively; and
human immunoglobulin VL-chain CDR1, CDR2, and CDR3 of a polypeptide
consisting of amino-acid sequences represented by SEQ ID NOS: 10, 11, and 12,
respectively.

2. (Currently Amended) An isolated human antibody, comprising:
a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 3;
and
a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 9.

3. (Currently Amended) An isolated human antibody, comprising:
ligation of a polypeptide consisting of an amino-acid sequence represented by SEQ
ID NO: 3; and
~~ligation of~~ a polypeptide consisting of an amino-acid sequence represented by SEQ
ID NO: 9.

4. (Cancelled)

5. (Cancelled)

6. (Cancelled)

7. (Currently Amended) An isolated gene encoding ~~the~~ a human antibody ~~according~~
~~to any one of Claims 1-3 and 5.~~ comprising:
human immunoglobulin VH-chain CDR1, CDR2, and CDR3 of a polypeptide
consisting of amino-acid sequences represented by SEQ ID NOS: 4, 5, and 6,
respectively; and
human immunoglobulin VL-chain CDR1, CDR2, and CDR3 of a peptide consisting
of amino-acid sequences represented by SEQ ID NOS: 10, 11, and 12, respectively.

8. (Currently Amended) The gene according to Claim 7, including as an open reading frame the nucleic acid sequence of a base sequence represented by SEQ ID NO: 1 or 7.

9. (Previously Presented) A recombinant expression vector, comprising the gene according to Claim 7.

10. (Previously Presented) A transformant, comprising the gene according to Claim 7 introduced therein.

11. (Previously Presented) A method for producing a human antibody against human interleukin-18 by causing a host to express the gene according to Claim 7.

12. (Currently Amended) A detector for human interleukin-18, the detector using either (1) the antibody according to any one of Claims 1-3 or 37-39 ~~and 5, or (2) a modified antibody comprising the human antibody according to any one of Claims 1 to 5 and a modification agent binding thereto.~~

13. (Currently Amended) An immunological disease diagnostic kit for measuring an amount of human interleukin-18 contained in a test sample the human interleukin-18 antibody according to any one of claims 1-3 or 37-39; and a carrier on which the human interleukin 18 antibody is immobilized; ~~by using either (1) the antibody according to any one of Claims 1-3 and 5, or (2) a human interleukin-18 detecting reagent including a modified antibody comprising the human antibody according to any one of Claims 1-3 and 5 and a modification agent binding thereto.~~

14. (Currently Amended) A method for diagnosing immunological disease in accordance with an amount of human interleukin-18 contained in a test sample ~~and the amount of human interleukin-18 being~~ measured by using ~~the detecting reagent according to Claim 13;~~ a human antibody, comprising:

human immunoglobulin VH-chain CDR1, CDR2, and CDR3 of a polypeptide consisting of amino-acid sequences represented by SEQ ID NOS: 4, 5, and 6, respectively; and

human immunoglobulin VL-chain CDR1, CDR2, and CDR3 of a peptide consisting of amino-acid sequences represented by SEQ ID NOS: 10, 11, and 12, respectively.

15. (Cancelled)

16. (Currently Amended) ~~The~~ A human interleukin-18 activity inhibitor ~~according to Claim 15, wherein the~~ comprising a human interleukin-18 antagonist as an active ingredient, the human interleukin-18 antagonist being the human antibody according to any one of claims 1-3 or 37-39~~1-4~~, ~~is any one of following substances selected from:~~

- ~~(i) the human antibody according to any one of Claims 1-3 and 5;~~
- ~~(ii) a modified antibody comprising the human antibody according to any one of Claims 1-3 and 5 and a modification agent binding thereto; and~~
- ~~(iii) a low molecular compound obtained through molecular designing in accordance with an antigen determining region on human interleukin-18, the antigen determining region being recognized by either (1) the antibody according to (i), or (2) the modified antibody according to (ii).~~

17. (Previously Presented) A gene therapy agent, comprising the gene according to Claim 7.

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Cancelled)

25. (Previously Presented) A recombinant expression vector, comprising the gene according to Claim 8.

26. (Previously Presented) A transformant, comprising the gene according to Claim 8 introduced therein.

27. (Currently Amended) A method for producing a human antibody against human interleukin-18 by causing a host to express the gene according to Claim 8, the human antibody being produced by the expression of the gene.

28. (Previously Presented) A gene therapy agent, comprising the gene according to Claim 8.

29. (Currently Amended) ~~A immunological disease treatment agent, comprising the~~
The human interleukin-18 activity inhibitor according to Claim 16, which is used for
treating immunological disease.

30. (Canceled)

31. (New) An isolated gene encoding a human antibody, wherein the gene encodes:
a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 3;
and
a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 9.

32. (New) An isolated gene encoding a human antibody, wherein the gene encodes:
ligation of a polypeptide consisting of an amino-acid sequence represented by SEQ
ID NO: 3 a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO:
9.